A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)

BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis, with significant impact on quality of life and functional status. Whilst biologic disease modifying anti-rheumatic drugs (bDMARD) such as tumour necrosis factor-inhibitor (TNFi) agents have revolutionised outcomes in RA, earl...

Descripción completa

Detalles Bibliográficos
Autores principales: Dumitru, Raluca B., Horton, Sarah, Hodgson, Richard, Wakefield, Richard J., Hensor, Elizabeth M. A., Emery, Paul, Buch, Maya H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743173/
https://www.ncbi.nlm.nih.gov/pubmed/26847108
http://dx.doi.org/10.1186/s12891-016-0915-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743173/
https://www.ncbi.nlm.nih.gov/pubmed/26847108
http://dx.doi.org/10.1186/s12891-016-0915-0

Ejemplares similares